Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122028) titled 'Efficacy and Safety of Glofitamab in the Real-World Treatment of Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma' on April 8.

Study Type: Observational study

Study Design: Sequential

Primary Sponsor: Henan Cancer Hospital

Condition: Primary refractory and early relapsed diffuse large B-cell lymphoma (PR/ER DLBCL)

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-04-30

Target Sample Size: Glofitamab Treatment Group:20;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=308690

Published by HT Dig...